Abstract

Lysophosphatidic acid (LysoPA) has been proposed to be involved in the pathogenesis of various cancers. Moreover, glycero-lysophospholipids (glycero-LysoPLs) other than LysoPA are now emerging as novel lipid mediators. Therefore, we aimed to elucidate the possible involvement of glycero-LysoPLs in the pathogenesis of gastric cancer by measuring glycero-LysoPLs, autotaxin (ATX), and phosphatidylserine-specific phospholipase A1 (PS-PLA1) in ascites obtained from patients with gastric cancer and those with cirrhosis (as a control). We observed that after adjustments according to the albumin levels, the lysophosphatidylserine (LysoPS) and lysophosphatidylglycerol (LysoPG) levels were significantly higher, while the LysoPA and ATX levels were lower, in the ascites from patients with gastric cancer. We also found that multiple regression analyses revealed that ATX was selected as a significant explanatory factor for all the detectable LysoPA species only in the cirrhosis group and that a significant positive correlation was observed between LysoPS and PS-PLA1 only in the gastric cancer group. In conclusion, the LysoPA levels might be determined largely by LysoPC and LysoPI (possible precursors) and the PS-PLA1-mediated pathway might be involved in the production of LysoPS in gastric cancer. Glycero-LysoPLs other than LysoPA might also be involved in the pathogenesis of cancer directly or through being converted into LysoPA.

Highlights

  • Lysophosphatidic acid (LysoPA) has been proposed to be involved in the pathogenesis of various cancers

  • The concentrations of total LysoPC, LysoPS, LysoPI, LysoPE, and LysoPG were significantly higher in the ascites from the subjects with gastric cancer, while the concentration of LysoPA was not different between these groups

  • The LysoPC and LysoPI levels were higher in the gastric cancer group without adjustments for ALB, while significant differences in most of the LysoPC and LysoPI species were not observed after adjustment according to the ALB level except for the 18:2 and 20:4 LysoPC levels

Read more

Summary

Introduction

Lysophosphatidic acid (LysoPA) has been proposed to be involved in the pathogenesis of various cancers. Glycero-lysophospholipids (glycero-LysoPLs) possess a glycerol backbone with one fatty-acid chain and one hydrophilic compartment This molecular family includes lysophosphatidic acid (LysoPA), lysophosphatidylcholine (LysoPC), lysophosphatidylethanolamine (LysoPE), lysophosphatidylglycerol (LysoPG), lysophosphatidylinositol (LysoPI), and lysophosphatidylserine (LysoPS) [1, 2]. Among these glycero-LysoPLs, LysoPA has been most studied in various fields, including oncology; LysoPA works on six kinds of G protein-coupled receptors (GPCRs), LysoPA receptors 1–6, located on the cell membrane and reportedly stimulates proliferation, migration, invasion, tumor angiogenesis, and resistance to the chemotherapy of cancer cells [3,4,5,6].

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.